A caffeine-triggered switch that turns CRISPR gene editing on and off inside cells could one day improve cancer therapy.

Pulse BioSciences’ CTO knows what it takes to create successful medtech and sometimes, it takes partnering with the competition.

Jade Biosciences (NASDAQ:JBIO) outlined its strategy and near-term milestones at the Oppenheimer Life Sciences Conference, ...

LigaChem Biosciences said on the 24th that it signed a technology licensing agreement with U.S. biotech company NovaRock Biotherapeutics for an antibody targeting a new anticancer target to develop an ...

Scantox Group today announced it has acquired the nonclinical genomic safety business of TwinStrand Biosciences, Inc. through ...

Scientists at Texas A&M are turning an everyday pick-me-up into a high-tech medical switch. By combining caffeine with CRISPR ...

Alume Biosciences delivers positive topline results for three pivotal trials of Bevonescein, advancing toward NDA ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the ...

Upon successful development, SK bioscience with its Consortium partners plan to pursue entry into major advanced markets, including Europe's Northern Hemisphere market, and explore additional business ...

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central ...

Atrandi Biosciences, a life sciences tools company advancing single-cell analysis, today announced it will present new scientific data and platform innovations at the Society for Laboratory Automation ...

BOSTON, February 06, 2026--(BUSINESS WIRE)--Atrandi Biosciences, a life sciences tools company advancing single-cell analysis, today announced it will present new scientific data and platform ...